Search results for "hepatitis c virus"

showing 10 items of 403 documents

Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus.

2018

OBJECTIVE: To optimize the management of patients with chronic hepatitis C virus (HCV). MATERIALS AND METHODS: We developed two questionnaires to determine Italian healthcare professionals’ opinions on the overall management of HCV chronic liver disease and the use of direct-acting antivirals (DAAs) in the treatment of HCV. A Delphi consensus method using the RAND/UCLA appropriateness method was used to determine opinions of an expert panel (EP) of specialists. RESULTS: Overall 443 physicians from 167 Italian centres completed the two questionnaires. The EP confirmed the importance of collaboration with general practitioners (GPs) and HCV testing in high-risk groups, but did not agree on tr…

AdultAged 80 and overLiver CirrhosisMaleConsensusGenotypedelphi methodhepatitis c virus; direct-acting antivirals; delphi method; consensus; adult; aged 80 and over; antiviral agents; consensus; elasticity imaging techniques; female; genotype; hepacivirus; hepatitis c chronic; humans; liver cirrhosis; male; middle aged; surveys and questionnairesHepacivirushepatitis c virusHepatitis C ChronicMiddle AgedAntiviral AgentschronicagedSurveys and QuestionnairesHCV80 and overElasticity Imaging TechniquesHumansFemalehepatitis cdirect-acting antiviralsEuropean review for medical and pharmacological sciences
researchProduct

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

2008

The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection is probably underestimated because of the increasing spread of this virus worldwide, especially in developing countries. In these patients, anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy may aggravate hepatitis and increase viremia. We evaluated the safety of these treatments, which remain controversial.Thirty-one HCV-positive patients (23 women, 8 men, mean age 59+/-13 yrs, mean disease duration 13+/-11.5 SD yrs) with active RA [Disease Activity Score 28 (DAS28)3.2] unresponsive to conventional therapies were treated with TNF-alpha blockers (infliximab 11, etanercept 17, adalimumab 3) at…

AdultAged 80 and overMalerheumatoid arthritissafetyhepatitis c virus; rheumatoid arthritis; safety; tumor necrosis factor-α blockerTumor Necrosis Factor-alphaAdalimumabHepatitis C ChronicMiddle AgedViral Loadhepatitis c virusInfliximabEtanerceptArthritis Rheumatoidtumor necrosis factor-α blockerAdalimumab Etanercept InfliximabAntirheumatic AgentsHumansFemaleanti-tumor necrosis factor-alpha; rheumatoid arthritis; hepatitis CAgedFollow-Up StudiesRetrospective Studies
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct

HCV viraemia is more important than genotype as a predictor of response to interferon in sicily (Southern Italy)

1996

Abstract Background/Aims: To investigate host- and virus-related factors predictive of early and sustained alanine aminotransferase normalization after interferon therapy for HCV-related chronic liver disease, in an area where genotype 1 is highly prevalent. Methods: We studied 100 patients with HCV-RNA positive chronic liver disease (73 chronic hepatitis and 27 cirrhosis) undergoing alpha-interferon treatment. Thirty-four patients had an early response but relapsed, 15 patients remained into sustained response for at least 12 months after therapy, and 51 patients did not respond. Serum HCV-RNA levels were assessed by bDNA (Chiron), and genotype by LiPA (Innogenetics) and by sequencing of t…

AdultLiver CirrhosisMaleCirrhosisGenotypeHepatitis C virusMolecular Sequence DataAlpha interferonChronic liver diseasemedicine.disease_causeAntiviral AgentsGenotypePrevalenceBDNA testmedicineHumansViremiaSicilyInterferon alfaBase SequenceHepatologybusiness.industryInterferon-alphaAlanine TransaminaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CTreatment OutcomeLiverChronic DiseaseImmunologyNucleic Acid ConformationFemalebusinessmedicine.drugJournal of Hepatology
researchProduct

Impact of comorbidities on the severity of chronic hepatitis B at presentation.

2011

AIM: To evaluate the clinical relevance of each cofactor on clinical presentation of chronic hepatitis B. METHODS: Out of 1366 hepatitis B surface antigen (HBsAg) positive subjects consecutively observed in 79 Italian hospitals, 53 (4.3%) showed as the only cofactor hepatitis D virus (HDV) infection [hepatitis B virus (HBV)/HDV group], 130 (9.5%) hepatitis C virus (HCV) (group HBV/HCV), 6 (0.4%) human immunodeficiency virus (HIV) (group HBV/HIV), 138 (10.2%) alcohol abuse (group HBV/alcohol); 109 (8.0%) subjects had at least two cofactors and 924 were in the cofactor-free (CF) group. RESULTS: Compared with patients in group CF those in group HBV/alcohol were older and more frequently had ci…

AdultLiver CirrhosisMaleHBsAgmedicine.medical_specialtyCirrhosisBrief ArticleHepatitis C virusAlcohol abuseLiver CirrhosiHIV InfectionsComorbiditymedicine.disease_causeGastroenterologyChronic hepatitis BSeverity of Illness IndexLiver diseaseHepatitis B ChronicHepatitis B virus/hepatitis C virus dual infectionInternal medicinemedicineHBVHumansAge FactorHIV InfectionAgedHepatitis B virusbusiness.industryGastroenterologyAge Factorsvirus diseasesGeneral MedicineHepatitis CMiddle Agedmedicine.diseaseHepatitis DHepatitis Cdigestive system diseasesHepatitis DAlcoholismItalyImmunologyFemaleHepatitis D virusbusinessHepatitis B virus/hepatitis D virus dual infectionHuman
researchProduct

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases

2005

Knowledge of the current epidemiology of chronic liver disease in Italy is mostly obsolete and fragmentary for the lack of up-to-date consistent data. In 2001, a 6-month prevalence study was undertaken in 79 hospitals to assess the characteristics of chronic liver disease in Italy. Both prevalent and incident cases were enrolled. A total of 9,997 patients were recruited, of whom 939 (9.4%) had normal liver biochemistry, 6,210 (62.1%) had chronic hepatitis, 1,940 (19.4%) had liver cirrhosis, and 341 (3.4%) had hepatocellular carcinoma (HCC). In 567 patients (5.7%) the diagnosis was not established. Hepatitis C virus (HCV) was found in 69.9% of the patients and was the only etiological factor…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCarcinoma HepatocellularCirrhosisalcohol abuseHepatitis C virusHepacivirusChronic liver diseasemedicine.disease_causeRisk FactorsVirologyPrevalencemedicineHBVHumansAgedbusiness.industryIncidenceLiver DiseasesLiver NeoplasmsHepatitis CMiddle AgedHepatitis BHepatitis Bmedicine.diseaseHepatitis CVirologyAlcoholismInfectious DiseasesItalyHepatocellular carcinomaChronic DiseaseHCVFemaleViral hepatitisbusiness
researchProduct

Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.

2008

Iron overload and hepatitis virus C infection cause liver fibrosis in thalassemics. In a monocentric retrospective analysis of liver disease in a cohort of 191 transfusion-dependent thalassemics, in 126 patients who had undergone liver biopsy (mean age 17.2 years; 58 hepatitis virus C-RNA positive and 68 hepatitis virus C-RNA negative) the liver iron concentration (median 2.4 mg/gr dry liver weight) was closely related to serum ferritin levels (R = 0.58; p<0.0001). Male gender (OR 4.12) and serum hepatitis virus C-RNA positivity (OR 11.04) were independent risk factors for advanced liver fibrosis. The majority of hepatitis virus C-RNA negative patients with low iron load did not develop liv…

AdultLiver CirrhosisMaleLiver Iron ConcentrationCirrhosisIron OverloadAdolescentHepatitis C virusBiopsyHepacivirusSettore MED/08 - Anatomia Patologicamedicine.disease_causeCohort StudiesLiver diseasethalassemic iron chronic hepatitis CMedicineHumansRetrospective StudiesSettore MED/12 - Gastroenterologiamedicine.diagnostic_testbusiness.industryTransfusion ReactionHematologyHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseLiverLiver biopsyImmunologySplenectomyThalassemiaFemalebusinessHepatic fibrosisViral loadHaematologica
researchProduct

Generalized Linear Model (GLM) framework for the association of host variables and viral strains with liver fibrosis in HCV/HIV coinfected patients

2012

Chronic hepatitis C virus (HCV) infection is the main cause of advanced and end-stage liver disease world-wide, and an important factor of morbidity and mortality in Human Immunodeficiency virus-1 (HIV-1) co-infected individuals. Whereas the genetic variability of HCV has been studied extensively in monoinfected patients, comprehensive analyses of both patient and virus characteristics are still scarce in HCV/HIV co-infection. In order to find correlates for liver damage, we sought to analyze demographic, epidemiological and clinical features of HCV/HIV co-infected patients along with the genetic makeup of HCV (viral subtypes and lineage studied by nucleotide sequencing and phylogenetic ana…

AdultLiver CirrhosisMaleMicrobiology (medical)medicine.medical_specialtyHepatitis C virusHIV InfectionsHepacivirusViral Nonstructural ProteinsBiologymedicine.disease_causeModels BiologicalMicrobiologyViruschemistry.chemical_compoundLiver diseaseFibrosisEpidemiologyGeneticsmedicineHumansGenetic variabilityMolecular BiologyNS5BPhylogenyEcology Evolution Behavior and SystematicsRetrospective StudiesPhylogenetic treeCoinfectionvirus diseasesHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyLinear ModelsFemaleInfection, Genetics and Evolution
researchProduct

Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients.

2013

Background & Aims: Unhealthy food intake, specifically fructose, has been associated with metabolic alterations and with the severity of liver fibrosis in patients with non-alcoholic fatty liver disease. In a cohort of patients with genotype 1 chronic hepatitis C (G1 CHC), we tested the association of fructose intake with the severity of liver histology. Methods: Anthropometric and metabolic factors, including waist circumference (WC), waist-to-hip ratio (WHR), dorso-cervical lipohypertrophy and HOMA were assessed in 147 consecutive biopsy-proven G1 CHC patients. Food intake, namely industrial and fruit fructose, was investigated by a three-day structured interview and a computed database. …

AdultLiver CirrhosisMalePathologymedicine.medical_specialtyGenotypeHepatitis C virusLIVER FIBROSISmedicine.disease_causeGastroenterologychemistry.chemical_compoundWaist–hip ratioHcv fructose fibrosisInternal medicineFRUCTOSEmedicineHumansIndustryAgedSettore MED/12 - GastroenterologiaHepatologybusiness.industryFatty liverLipohypertrophyFructoseHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasechemistryFruitFemaleSteatosisSteatohepatitishepatitis Cbusiness
researchProduct

Increased intrahepatic and circulating levels of endoglin, a TGF-β1 co-receptor, in patients with chronic hepatitis C virus infection: relationship t…

2006

Endoglin, a transforming growth factor (TGF)-beta1 co-receptor, has been associated with renal and cutaneous fibrosis, as overexpression of this protein has been observed in biopsies from patients with glomerulosclerosis and scleroderma, respectively. Our aim was to evaluate whether endoglin may be associated with hepatic fibrosis featuring chronic hepatitis C virus (HCV) infection. Fifty-two anti-HCV+ patients, five anti-HCV- patients and 27 healthy subjects were studied. Western blot and immunohistochemistry were used to quantify the expression levels of endoglin and TGF-beta1 in liver biopsy samples, and serum concentrations of endoglin and hyaluronic acid were determined by enzyme-linke…

AdultLiver CirrhosisMalePathologymedicine.medical_specialtyHepatitis C virusBlotting WesternEnzyme-Linked Immunosorbent AssayReceptors Cell SurfaceSerum Hyaluronic Acidmedicine.disease_causeAntigens CDFibrosishemic and lymphatic diseasesVirologyotorhinolaryngologic diseasesmedicineHumansHyaluronic AcidHepatologymedicine.diagnostic_testbusiness.industryEndoglinHepatitis CHepatitis C ChronicMiddle AgedEndoglinmedicine.diseaseFibrosisImmunohistochemistryInfectious DiseasesLiverLiver biopsyHepatic stellate cellFemaleHepatic fibrosisbusinessBiomarkersJournal of Viral Hepatitis
researchProduct